ZAK α/P38 kinase signaling pathway regulates hematopoiesis by activating the NLRP1 inflammasome
In conclusion, our results reveal that the NLRP1 inflammasome regulates hematopoiesis and pave the way to develop novel therapeutic strategies for the treatment of hematopoietic alterations associated with chronic inflammatory and rare diseases.PMID:37675820 | DOI:10.15252/emmm.202318142 (Source: Molecular Medicine)
Source: Molecular Medicine - September 7, 2023 Category: Molecular Biology Authors: Lola Rodr íguez-Ruiz Juan M Lozano-Gil Elena Naranjo-S ánchez Elena Mart ínez-Balsalobre Alicia Mart ínez-López Christophe Lachaud Miguel Blanquer Toan K Phung Diana Garc ía-Moreno Mar ía L Cayuela Sylwia D Tyrkalska Ana B P érez-Oliva Victoriano Source Type: research
Nilotinib alleviates paraquat-induced hepatic and pulmonary injury in rats via the Nrf2/Nf-kB axis
Int Immunopharmacol. 2023 Sep 5;124(Pt A):110886. doi: 10.1016/j.intimp.2023.110886. Online ahead of print.ABSTRACTBACKGROUND: Paraquat (PQ, 1,1'-dimethyl-4-4'-bipyridinium dichloride) is a highly toxic quaternary ammonium herbicide widely used in agriculture. It exerts its toxic effects mainly as a result of its redox cycle via the production of superoxide anions in organisms, leading to an imbalance in the redox state of the cell causing oxidative damage and finally cell death. The aim of this study was to estimate the beneficial protective role of nilotinib (NIL) on PQ-induced hepatic and pulmonary toxicity in rats.METH...
Source: International Immunopharmacology - September 7, 2023 Category: Allergy & Immunology Authors: Azza R Elkholy Ahmed R El-Sheakh Ghada M Suddek Source Type: research
Nilotinib alleviates paraquat-induced hepatic and pulmonary injury in rats via the Nrf2/Nf-kB axis
Int Immunopharmacol. 2023 Sep 5;124(Pt A):110886. doi: 10.1016/j.intimp.2023.110886. Online ahead of print.ABSTRACTBACKGROUND: Paraquat (PQ, 1,1'-dimethyl-4-4'-bipyridinium dichloride) is a highly toxic quaternary ammonium herbicide widely used in agriculture. It exerts its toxic effects mainly as a result of its redox cycle via the production of superoxide anions in organisms, leading to an imbalance in the redox state of the cell causing oxidative damage and finally cell death. The aim of this study was to estimate the beneficial protective role of nilotinib (NIL) on PQ-induced hepatic and pulmonary toxicity in rats.METH...
Source: International Immunopharmacology - September 7, 2023 Category: Allergy & Immunology Authors: Azza R Elkholy Ahmed R El-Sheakh Ghada M Suddek Source Type: research
Cancers, Vol. 15, Pages 4354: Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis
In conclusion, the overall prevalence of hematological AEs by TKI type was: dasatinib > bosutinib > imatinib > nilotinib. Study limitations include inability to normalize for dosage and treatment duration. (Source: Cancers)
Source: Cancers - August 31, 2023 Category: Cancer & Oncology Authors: Olivia Kronick Xinyu Chen Nidhi Mehra Armon Varmeziar Rachel Fisher David Kartchner Vamsi Kota Cassie S. Mitchell Tags: Systematic Review Source Type: research
IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways
Sci Signal. 2023 Aug 29;16(800):eadd7705. doi: 10.1126/scisignal.add7705. Epub 2023 Aug 29.ABSTRACTCell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the same signaling pathways frequently support stemness in both LSCs and normal hematopoietic stem cells (HSCs), making LSCs difficult to therapeutically target. In cell lines and patient samples, we found that interleukin-33 (IL-33) signaling promoted stemness only in leukemia c...
Source: Science Signaling - August 29, 2023 Category: Biomedical Science Authors: Pascal Naef Ramin Radpour Carla A Jaeger-Ruckstuhl Nils Bodmer Gabriela M Baerlocher Hartmut Doehner Konstanze Doehner Carsten Riether Adrian F Ochsenbein Source Type: research
IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways
Sci Signal. 2023 Aug 29;16(800):eadd7705. doi: 10.1126/scisignal.add7705. Epub 2023 Aug 29.ABSTRACTCell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the same signaling pathways frequently support stemness in both LSCs and normal hematopoietic stem cells (HSCs), making LSCs difficult to therapeutically target. In cell lines and patient samples, we found that interleukin-33 (IL-33) signaling promoted stemness only in leukemia c...
Source: Science Signaling - August 29, 2023 Category: Biomedical Science Authors: Pascal Naef Ramin Radpour Carla A Jaeger-Ruckstuhl Nils Bodmer Gabriela M Baerlocher Hartmut Doehner Konstanze Doehner Carsten Riether Adrian F Ochsenbein Source Type: research
IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways
Sci Signal. 2023 Aug 29;16(800):eadd7705. doi: 10.1126/scisignal.add7705. Epub 2023 Aug 29.ABSTRACTCell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the same signaling pathways frequently support stemness in both LSCs and normal hematopoietic stem cells (HSCs), making LSCs difficult to therapeutically target. In cell lines and patient samples, we found that interleukin-33 (IL-33) signaling promoted stemness only in leukemia c...
Source: Science Signaling - August 29, 2023 Category: Biomedical Science Authors: Pascal Naef Ramin Radpour Carla A Jaeger-Ruckstuhl Nils Bodmer Gabriela M Baerlocher Hartmut Doehner Konstanze Doehner Carsten Riether Adrian F Ochsenbein Source Type: research
IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways
Sci Signal. 2023 Aug 29;16(800):eadd7705. doi: 10.1126/scisignal.add7705. Epub 2023 Aug 29.ABSTRACTCell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the same signaling pathways frequently support stemness in both LSCs and normal hematopoietic stem cells (HSCs), making LSCs difficult to therapeutically target. In cell lines and patient samples, we found that interleukin-33 (IL-33) signaling promoted stemness only in leukemia c...
Source: Science Signaling - August 29, 2023 Category: Biomedical Science Authors: Pascal Naef Ramin Radpour Carla A Jaeger-Ruckstuhl Nils Bodmer Gabriela M Baerlocher Hartmut Doehner Konstanze Doehner Carsten Riether Adrian F Ochsenbein Source Type: research
IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways
Sci Signal. 2023 Aug 29;16(800):eadd7705. doi: 10.1126/scisignal.add7705. Epub 2023 Aug 29.ABSTRACTCell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the same signaling pathways frequently support stemness in both LSCs and normal hematopoietic stem cells (HSCs), making LSCs difficult to therapeutically target. In cell lines and patient samples, we found that interleukin-33 (IL-33) signaling promoted stemness only in leukemia c...
Source: Science Signaling - August 29, 2023 Category: Biomedical Science Authors: Pascal Naef Ramin Radpour Carla A Jaeger-Ruckstuhl Nils Bodmer Gabriela M Baerlocher Hartmut Doehner Konstanze Doehner Carsten Riether Adrian F Ochsenbein Source Type: research
IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways
Sci Signal. 2023 Aug 29;16(800):eadd7705. doi: 10.1126/scisignal.add7705. Epub 2023 Aug 29.ABSTRACTCell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the same signaling pathways frequently support stemness in both LSCs and normal hematopoietic stem cells (HSCs), making LSCs difficult to therapeutically target. In cell lines and patient samples, we found that interleukin-33 (IL-33) signaling promoted stemness only in leukemia c...
Source: Science Signaling - August 29, 2023 Category: Biomedical Science Authors: Pascal Naef Ramin Radpour Carla A Jaeger-Ruckstuhl Nils Bodmer Gabriela M Baerlocher Hartmut Doehner Konstanze Doehner Carsten Riether Adrian F Ochsenbein Source Type: research
Evaluation of time to onset and outcome of cardiac adverse events associated with nilotinib using post-marketing surveillance
CONCLUSIONS: We focused on CAEs caused by nilotinib as post-marketing AEs. Some cases resulted in serious outcomes. Patients should be monitored for signs of onset of these AEs not only at the start of administration, but for a long period of time.PMID:37598671 | DOI:10.1159/000533325 (Source: Oncology)
Source: Oncology - August 20, 2023 Category: Cancer & Oncology Authors: Yuko Kanbayashi Asuka Kojima Haruka Wakabayashi Tadashi Shimizu Mayako Uchida Source Type: research
Evaluation of time to onset and outcome of cardiac adverse events associated with nilotinib using post-marketing surveillance
CONCLUSIONS: We focused on CAEs caused by nilotinib as post-marketing AEs. Some cases resulted in serious outcomes. Patients should be monitored for signs of onset of these AEs not only at the start of administration, but for a long period of time.PMID:37598671 | DOI:10.1159/000533325 (Source: Oncology)
Source: Oncology - August 20, 2023 Category: Cancer & Oncology Authors: Yuko Kanbayashi Asuka Kojima Haruka Wakabayashi Tadashi Shimizu Mayako Uchida Source Type: research
Evaluation of time to onset and outcome of cardiac adverse events associated with nilotinib using post-marketing surveillance
CONCLUSIONS: We focused on CAEs caused by nilotinib as post-marketing AEs. Some cases resulted in serious outcomes. Patients should be monitored for signs of onset of these AEs not only at the start of administration, but for a long period of time.PMID:37598671 | DOI:10.1159/000533325 (Source: Oncology)
Source: Oncology - August 20, 2023 Category: Cancer & Oncology Authors: Yuko Kanbayashi Asuka Kojima Haruka Wakabayashi Tadashi Shimizu Mayako Uchida Source Type: research
Evaluation of time to onset and outcome of cardiac adverse events associated with nilotinib using post-marketing surveillance
CONCLUSIONS: We focused on CAEs caused by nilotinib as post-marketing AEs. Some cases resulted in serious outcomes. Patients should be monitored for signs of onset of these AEs not only at the start of administration, but for a long period of time.PMID:37598671 | DOI:10.1159/000533325 (Source: Oncology)
Source: Oncology - August 20, 2023 Category: Cancer & Oncology Authors: Yuko Kanbayashi Asuka Kojima Haruka Wakabayashi Tadashi Shimizu Mayako Uchida Source Type: research
Evaluation of time to onset and outcome of cardiac adverse events associated with nilotinib using post-marketing surveillance
CONCLUSIONS: We focused on CAEs caused by nilotinib as post-marketing AEs. Some cases resulted in serious outcomes. Patients should be monitored for signs of onset of these AEs not only at the start of administration, but for a long period of time.PMID:37598671 | DOI:10.1159/000533325 (Source: Oncology)
Source: Oncology - August 20, 2023 Category: Cancer & Oncology Authors: Yuko Kanbayashi Asuka Kojima Haruka Wakabayashi Tadashi Shimizu Mayako Uchida Source Type: research
